ArticleJournal of medical physics
Can Rectal Cancer Patients with Complete Response to Neoadjuvant Chemoradiotherapy Avoid Surgery?
Article in Journal of medical physics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Rectal cancer is one of the most common malignancies worldwide. Neoadjuvant chemoradiotherapy (nCRT) is now the standard treatment for locally advanced rectal cancer. The aims of this study are to assess the feasibility of the "Watch and Wait" (WW) pathway for patients who achieved complete clinical response compared with surgery in patients treated with neoadjuvant therapy for rectal cancer. In addition, we evaluated the accuracy of magnetic resonance imaging (MRI) in assessing the residual cancer after neoadjuvant therapy. Methods: We conducted a retrospective review of patients who had neoadjuvant therapy for rectal cancer with MRI restaging. All patients were followed-up for a minimum of 2 years to assess the efficacy of (WW) pathway. MRI results were compared with either excision results or 3-month follow-up to assess MRI accuracy. Results: We included 41 patients. Average age was 69 ± 10 years. Eleven females and 30 males were included. The 2-year survival and disease-free survival (DFS) rates were 73% and 61.5% for the surgical group and 53.3% and 46.7% for the (WW) group, respectively. MRI sensitivity for detecting residual tumor was 57.69% with an accuracy rate of 70.73%, while when combining with other tests, the sensitivity increased to 80.77% with an accuracy rate of 85.37%. Conclusion: "Watch and Wait" approach is a safe and acceptable approach guided by regular monitoring and careful selection of the patients. There was no significant difference in 2-year survival and DFS between patients who had surgery and patients who opted for (WW) pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.